1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Analysis of Gilead Sciences

Analysis of Gilead Sciences

  • April 2016
  • -
  • Aruvian's R'search
  • -
  • 120 pages

Based in the United States, Gilead Sciences is a global leader in the marketing and development of anti-infective drugs. The company has approved products for the treatment of Hepatitis B & C, HIV/AIDS, fungal infections and influenza.

Aruvian Research presents Analysis of Gilead Sciences. A complete and comprehensive analysis of Gilead Sciences, includes an overview of the industry the company operates in, a PEST Framework Analysis of the industry, and then moves on to analyzing the company itself.

Company analysis from Aruvian includes a history of Gilead Sciences, a business segment analysis of the segments Gilead Sciences operates through, a look at the organization structure of the company, a geographical operating segments analysis, an analysis of the company’s major competitors.

A financial analysis of Gilead Sciences is presented in the report which includes a ratio analysis, basic profit and loss analysis, presentation of the company balance sheet, and much more.

A SWOT Framework Analysis of Gilead Sciences completes this in-depth company analysis.

Table Of Contents

Analysis of Gilead Sciences
A. Executive Summary

B. Looking at the Industry
B.1 Industry Definition
B.2 Brief Profile of the Industry
B.3 Impacts on the Industry
B.4 Challenges Facing the Industry
B.5 Future Perspective

C. Industry PEST Framework Analysis
C.1 Political Aspects
C.2 Economic Aspects
C.3 Social Aspects
C.4 Technological Aspects

D. Looking at Gilead Sciences
D.1 Company Profile
D.2 History of the Company
D.3 Ownership Pattern in the Company
D.3.1 Major Holders
D.3.2 Major Direct Holders
D.3.3 Top Institutional Holders
D.3.4 Top Mutual Fund Holders
D.4 Organizational Divisions
D.5 Corporate Family
D.6 Profiling the Key Executives
D.7 Products and Services

E. Gilead Sciences: Looking at Business
E.1 Business Segments
E.2 Company Strategy
E.3 Geographical Segments
E.4 Company Subsidiaries

F. Gilead Sciences: SWOT Framework Analysis
F.1 Strengths to Build Upon
F.2 Weaknesses to Overcome
F.3 Opportunities to Exploit
F.4 Threats to Overcome

G. Profiling the Competition
G.1 Bristol-Myers Squibb Co
G.1.1 Corporate Profile
G.1.2 Business Segment Analysis
G.1.3 Financial Analysis
G.1.4 SWOT Analysis
G.2 Enzon Pharmaceuticals Inc.
G.2.1 Corporate Profile
G.2.2 Business Segment Analysis
G.2.3 Financial Analysis
G.2.4 SWOT Analysis
G.3 Hemispherx BioPharma, Inc.
G.3.1 Corporate Profile
G.3.2 Business Segment Analysis
G.3.3 Financial Analysis
G.3.4 SWOT Analysis

H. Gilead Sciences: Financial Analysis
H.1 Current Financials
H.2 Balance Sheet
H.3 Profit and Loss Statement
H.4 Ratio Analysis

I. Gilead Sciences: Future Perspective

J. Glossary of Terms

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Ulcerative Colitis: KOL Insight

Ulcerative Colitis: KOL Insight

  • $ 8085
  • Industry report
  • September 2016
  • by Firstword Pharma

Are UC biosimilars a real or perceived threat to branded drugs? Ulcerative colitis (UC) treatment is on the brink. Patents are ending on various branded drugs and clearing the way for an influx of biosimilars; ...

Colorectal Cancer KOL Insight 2016

Colorectal Cancer KOL Insight 2016

  • $ 8085
  • Industry report
  • October 2016
  • by Firstword Pharma

KOLs embrace novel MoAs as low survival rates drive search for new treatments Faced with persistently low survival rates, KOLs are calling for new approaches to treat late-stage colorectal cancer (CRC). ...

Hepatitis C: Kol Insight

September 2016 $ 8085

ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.